Related references
Note: Only part of the references are listed.Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Nicola Gaynor et al.
SEMINARS IN CANCER BIOLOGY (2022)
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Maria Vittoria Dieci et al.
CLINICAL CANCER RESEARCH (2022)
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
Ximing Yang et al.
FRONTIERS IN IMMUNOLOGY (2022)
T-cell-based breast cancer immunotherapy
Karolina Pilipow et al.
SEMINARS IN CANCER BIOLOGY (2021)
Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives
Kim Cao et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model
Haa-Na Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Tess A. O’Meara et al.
Oncotarget (2021)
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas et al.
FRONTIERS IN ONCOLOGY (2021)
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy
Avinash Eranki et al.
CLINICAL CANCER RESEARCH (2020)
Current status and limitations of immunotherapy for breast cancer
Yoshihisa Tokumaru et al.
SURGERY (2020)
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Atefeh Arab et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2020)
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL BREAST CANCER (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Alice Y. Ho et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy
Matthew J. Woodall et al.
CANCERS (2020)
Sex and Gender Influences on Cancer Immunotherapy Response
Azzurra Irelli et al.
BIOMEDICINES (2020)
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
Elena Shklovskaya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
Ravindra Pramod Deshpande et al.
CANCERS (2020)
Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
Yutian Zou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
Karsten A. Pilones et al.
ONCOIMMUNOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial (vol 25, pg 920, 2019)
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Assessing the interactions between radiotherapy and antitumour immunity
Clemens Grassberger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Laura Fancello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models
Ela Markovsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Time to abandon single-site irradiation for inducing abscopal effects
Eric D. Brooks et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients
Yuhan Zhang et al.
CANCER BIOLOGY & MEDICINE (2019)
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Liisa Chang et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy
Janet K. Horton et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Linda Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
Amit Maity et al.
BRITISH JOURNAL OF CANCER (2018)
Radiotherapy and immune response: the systemic effects of a local treatmentY
Heloisa de Andrade Carvalho et al.
CLINICS (2018)
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity
Pelagia G. Tsoutsou et al.
FRONTIERS IN ONCOLOGY (2018)
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Tiara T. Byrd et al.
CANCER RESEARCH (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents
Beibei Guo et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2017)
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Zishuo I. Hu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Effects of Smoking on Late Toxicity From Breast Radiation
Simona F. Shaitelman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Daniel A. Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Daniel A. Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells
Jan Willem Kleinovink et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy
Panagiotis Balermpas et al.
ONCOIMMUNOLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice
Debora de Melo Gagliato et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?
Zishuo I. Hu et al.
CURRENT BREAST CANCER REPORTS (2017)
CD8+tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)
Panagiotis Balermpas et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
The genomic landscape of breast cancer and its interaction with host immunity
Stephen Luen et al.
BREAST (2016)
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
Tomohiro F. Nishijima et al.
CANCER TREATMENT REVIEWS (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics
E. Colzani et al.
BRITISH JOURNAL OF CANCER (2014)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines
Elham Mohit et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
P. McGale et al.
LANCET (2014)
Breast cancer subtypes: response to radiotherapy and potential radiosensitisation
F. E. Langlands et al.
BRITISH JOURNAL OF RADIOLOGY (2013)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The Influence of BRCA1/BRCA2 Mutations on Toxicity Related to Chemotherapy and Radiotherapy in Early Breast Cancer Patients
Joanna Huszno et al.
ONCOLOGY (2013)
Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy
Mansoor M. Ahmed et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival-a retrospective multi-centre cohort study
L. Schwentner et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Steven A. Eschrich et al.
CLINICAL CANCER RESEARCH (2012)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Leisha A. Emens
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Risk of second breast cancer according to estrogen receptor status and family history
Christine Bouchardy et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
LANCET (2011)
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Systemic effects of local radiotherapy
Silvia C. Formenti et al.
LANCET ONCOLOGY (2009)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
Host antitumour immune responses to HIFU ablation
F. Wu et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2007)
Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first
Marc A. Bollet et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Cancer metastasis:: Building a framework
Gaorav P. Gupta et al.
CELL (2006)
Combining radiotherapy and immunotherapy: A revived partnership
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Immunologic response to cryoablation of breast cancer
MS Sabel et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
The immunological consequences of photodynamic treatment of cancer, a literature review
FH van Duijnhoven et al.
IMMUNOBIOLOGY (2003)
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
B Fisher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth:: An experimental study
JJA Joosten et al.
CRYOBIOLOGY (2001)
Share Paper
